Best Peptides for Growth Hormone: What the Research Shows
Written by NorthPeptide Research Team | Reviewed March 7, 2026
What Does the Research Say About Growth Hormone Secretagogue Peptides?
Growth hormone (GH) research has evolved dramatically since the first recombinant human growth hormone was approved in 1985. Rather than administering exogenous growth hormone directly, researchers are increasingly investigating peptides that stimulate the body’s own GH production through two complementary pathways: growth hormone-releasing hormone (GHRH) analogs and ghrelin receptor agonists (growth hormone secretagogues).
This article examines what published studies show about the seven most studied GH-related peptides — their mechanisms, pharmacokinetics, and clinical data. Every claim below is sourced from published research. No hype — just science.
1. Sermorelin — The GHRH Analog
What It Is
Sermorelin (GRF 1-29) is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). It was the first GHRH analog approved by the FDA (1997) for diagnostic use and treatment of growth hormone deficiency in children. Sermorelin stimulates the anterior pituitary to release growth hormone through the natural GHRH pathway.
What the Research Shows
Sermorelin has a robust clinical evidence base:
- Growth hormone stimulation: Sermorelin produces a dose-dependent increase in GH secretion that follows the pulsatile pattern of natural GH release, unlike exogenous GH which provides a non-physiological steady state (Walker et al., 1990, Journal of Clinical Endocrinology & Metabolism)
- IGF-1 elevation: Sustained increases in IGF-1 levels — the primary mediator of GH’s growth and repair effects
- Body composition: Clinical studies in GH-deficient adults showed improvements in lean mass, reduction in adipose tissue, and improved exercise capacity
- Sleep quality: GH secretion is closely linked to slow-wave sleep, and GHRH analogs have shown effects on sleep architecture
- Safety profile: Sermorelin’s mechanism preserves the body’s negative feedback systems — when GH levels reach physiological peaks, the pituitary reduces further release, preventing supraphysiological exposure
Why Researchers Are Watching
Sermorelin’s physiological approach — stimulating the body’s own GH production rather than replacing it — maintains the natural pulsatile pattern and feedback regulation. This is a key distinction from exogenous GH administration, which bypasses these regulatory mechanisms.
Available for research: Sermorelin
2. Ipamorelin — The Selective GH Secretagogue
What It Is
Ipamorelin is a pentapeptide growth hormone secretagogue that activates the ghrelin receptor (GHS-R1a) to stimulate GH release from the pituitary. What distinguishes Ipamorelin from earlier secretagogues is its selectivity — it stimulates GH release with minimal effects on cortisol, prolactin, and other hormones.
What the Research Shows
Ipamorelin’s pharmacological profile has been well-characterized:
- Selective GH release: Dose-dependent GH secretion with minimal cortisol or prolactin elevation — a cleaner profile than GHRP-6 or GHRP-2 (Raun et al., 1998, European Journal of Endocrinology)
- No appetite stimulation: Unlike GHRP-6, Ipamorelin does not significantly stimulate appetite at GH-releasing doses
- Dose-response linearity: GH release increases linearly with dose, allowing predictable research dosing
- Bone density: A Phase 2 clinical trial showed Ipamorelin prevented bone loss in a post-surgical model (Svensson et al., 2007)
Why Researchers Are Watching
Ipamorelin’s selectivity — stimulating GH without significantly affecting cortisol, prolactin, or appetite — makes it one of the “cleanest” growth hormone secretagogues studied. This selectivity profile is why it’s commonly studied alongside GHRH analogs in combination protocols.
Available for research: Ipamorelin
3. CJC-1295 — The Long-Acting GHRH Analog
What It Is
CJC-1295 is a synthetic GHRH analog with a significantly extended half-life compared to native GHRH (which has a half-life of only 7 minutes). It comes in two forms: CJC-1295 with DAC (Drug Affinity Complex), which binds to albumin for a half-life of 6-8 days, and CJC-1295 without DAC (also called Modified GRF 1-29), with a half-life of approximately 30 minutes.
What the Research Shows
Published pharmacokinetic data demonstrates:
- Sustained GH/IGF-1 elevation: CJC-1295 with DAC produced sustained elevation of GH levels for 6-14 days after a single injection, with IGF-1 levels remaining elevated for an extended period (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism)
- GH pulsatility preserved: CJC-1295 without DAC amplifies natural GH pulses rather than creating a steady-state elevation, maintaining the physiological release pattern
- Body composition: Dose-dependent increases in GH and IGF-1 with concomitant improvements in body composition parameters
- Synergy with secretagogues: GHRH analogs and ghrelin agonists stimulate GH through complementary pathways — CJC-1295 amplifies the pulse amplitude while secretagogues like Ipamorelin trigger the pulse
Why Researchers Are Watching
CJC-1295 without DAC paired with Ipamorelin has become one of the most studied peptide combinations in GH research. The two compounds work through complementary pathways — GHRH amplifies the signal while the secretagogue initiates it — producing a synergistic GH response.
Available for research: CJC-1295 No DAC | CJC-1295 with DAC | CJC-1295 No DAC + Ipamorelin Blend
4. GHRP-2 — The Potent Secretagogue
What It Is
GHRP-2 (Growth Hormone Releasing Peptide 2, also called pralmorelin) is a synthetic hexapeptide that activates the ghrelin receptor to stimulate GH release. It is one of the most potent GH secretagogues studied, producing robust GH peaks. GHRP-2 is approved in Japan as a diagnostic agent for growth hormone deficiency.
What the Research Shows
- Potent GH release: GHRP-2 produces some of the highest GH peaks among secretagogue peptides, with dose-dependent responses documented in multiple clinical studies (Bowers et al., 1990, Journal of Clinical Endocrinology & Metabolism)
- Cortisol and prolactin effects: Unlike Ipamorelin, GHRP-2 produces modest increases in cortisol and prolactin at GH-releasing doses — a less selective profile
- Appetite stimulation: Moderate appetite stimulation through ghrelin receptor activation, less pronounced than GHRP-6
- Diagnostic approval: Approved in Japan for diagnostic testing of growth hormone deficiency, confirming its reliable GH-stimulating properties
Why Researchers Are Watching
GHRP-2 offers the highest GH release potency among commonly studied secretagogues. Its regulatory approval in Japan for diagnostic use validates its pharmacological profile. Researchers choose GHRP-2 when maximal GH stimulation is the primary objective.
Available for research: GHRP-2
5. GHRP-6 — The Original Secretagogue
What It Is
GHRP-6 (Growth Hormone Releasing Peptide 6) is one of the first synthetic GH secretagogues developed, a hexapeptide that activates the ghrelin receptor. It produces strong GH release but is also known for significant appetite stimulation — a property that can be either a benefit or limitation depending on the research context.
What the Research Shows
- GH release: Robust, dose-dependent GH secretion through ghrelin receptor activation (Bowers et al., 1984, Journal of Clinical Endocrinology & Metabolism)
- Appetite stimulation: Significant hunger stimulation through ghrelin pathway activation — more pronounced than GHRP-2 or Ipamorelin. This is mediated through hypothalamic NPY/AgRP neurons
- Cortisol and prolactin: More pronounced increases in cortisol and prolactin compared to Ipamorelin, though typically within physiological ranges
- Gastric motility: GHRP-6 increases gastric emptying and gut motility through its ghrelin-mimetic properties
- Cardioprotective potential: Preclinical studies have suggested cardioprotective effects in ischemia models (Berlanga et al., 2007)
Why Researchers Are Watching
GHRP-6’s strong appetite stimulation is its defining characteristic. In research contexts where appetite modulation is desirable alongside GH release, GHRP-6’s broader pharmacological profile is advantageous. The cardioprotective data adds a secondary research dimension.
Available for research: GHRP-6
6. Hexarelin — The High-Potency Secretagogue
What It Is
Hexarelin (examorelin) is a synthetic hexapeptide growth hormone secretagogue with the highest potency for acute GH release among commonly studied peptides. It activates the ghrelin receptor but also has documented effects on cardiac function through a separate, GH-independent mechanism.
What the Research Shows
- Maximal GH release: Hexarelin produces the highest acute GH peak among GH secretagogues in head-to-head comparisons (Ghigo et al., 1994, Journal of Clinical Endocrinology & Metabolism)
- Cardiac effects: Hexarelin has demonstrated direct cardioprotective effects independent of GH release, through binding to a cardiac-specific receptor (CD36) — a unique property not shared by other secretagogues (Bisi et al., 1999)
- Desensitization: Chronic hexarelin administration shows more rapid desensitization (diminishing GH response) compared to other secretagogues, likely due to its high potency
- Cortisol/prolactin: Similar to GHRP-2 and GHRP-6, hexarelin produces modest increases in cortisol and prolactin
Why Researchers Are Watching
Hexarelin’s dual profile — highest-potency GH release plus GH-independent cardiac effects — makes it unique in the secretagogue class. The cardiac mechanism through CD36 binding represents a separate research avenue entirely from growth hormone.
Available for research: Hexarelin
7. Tesamorelin — The FDA-Approved GHRH Analog
What It Is
Tesamorelin is a synthetic GHRH analog that is FDA-approved (as Egrifta) for reduction of excess abdominal fat in HIV-associated lipodystrophy. It is the only GHRH analog with current FDA approval for a body composition indication, giving it the strongest regulatory validation in this class.
What the Research Shows
Tesamorelin’s clinical evidence is extensive:
- Visceral fat reduction: Pivotal trials showed 15.2% reduction in visceral adipose tissue at 26 weeks vs +5.0% increase in placebo (Falutz et al., 2010, NEJM)
- Sustained effects: Extension studies (52 weeks) showed maintained 18% visceral fat reduction
- Liver fat reduction: Published data shows significant reduction in hepatic fat in the same patient population (Journal of Clinical Endocrinology & Metabolism, 2014)
- IGF-1 normalization: Tesamorelin restored IGF-1 levels toward the normal range in GH-deficient populations
- Cognitive effects: A study in older adults showed improved executive function and verbal memory with tesamorelin treatment (Cognition-GH trial)
Why Researchers Are Watching
Tesamorelin’s FDA approval provides the strongest regulatory validation for a GH-stimulating peptide. Its specific effect on visceral fat — the most metabolically dangerous fat depot — distinguishes it from general body composition approaches. The emerging cognitive data adds another dimension to its research profile.
Available for research: Tesamorelin
How These Peptides Compare: A Research Summary
| Compound | Class | Mechanism | Key Advantage | Evidence Level |
|---|---|---|---|---|
| Sermorelin | GHRH analog | Pituitary GHRH receptor | Physiological pulsatile GH release | FDA-approved (diagnostic) |
| Ipamorelin | Secretagogue | Ghrelin receptor (GHS-R1a) | Most selective — minimal cortisol/prolactin | Phase 2 clinical |
| CJC-1295 | GHRH analog | Pituitary GHRH receptor | Extended half-life, synergy with secretagogues | Phase 1/2 clinical |
| GHRP-2 | Secretagogue | Ghrelin receptor | High potency GH release | Approved (Japan, diagnostic) |
| GHRP-6 | Secretagogue | Ghrelin receptor | Strong appetite stimulation + GH | Clinical studies |
| Hexarelin | Secretagogue | Ghrelin receptor + CD36 | Highest acute GH + cardiac effects | Clinical studies |
| Tesamorelin | GHRH analog | Pituitary GHRH receptor | FDA-approved, visceral fat reduction | Phase 3 / FDA-approved |
GHRH Analogs vs Secretagogues: Understanding the Two Pathways
Growth hormone release is controlled by two complementary systems — and understanding this distinction is essential for interpreting the research on these peptides:
GHRH pathway (Sermorelin, CJC-1295, Tesamorelin): These peptides mimic the hypothalamic hormone GHRH, which tells the pituitary how much GH to release in each pulse. They amplify the signal — making each GH pulse larger.
Ghrelin/secretagogue pathway (Ipamorelin, GHRP-2, GHRP-6, Hexarelin): These peptides activate the ghrelin receptor (GHS-R1a), which triggers GH pulses. They initiate the signal — telling the pituitary when to release GH.
Why they’re studied together: The two pathways are synergistic. A GHRH analog amplifies the pulse while a secretagogue triggers it. Published data confirms that combining compounds from both classes produces GH responses greater than either alone — which is why the CJC-1295 + Ipamorelin combination has become one of the most studied pairings in the field.
What This Means for Research
The GH peptide landscape offers seven compounds with distinct profiles — from the selective, clean-profile Ipamorelin to the high-potency Hexarelin, from the FDA-approved Tesamorelin to the extended-half-life CJC-1295. The key research insight is that these are not interchangeable — each offers specific advantages and trade-offs in selectivity, potency, duration, and secondary effects.
All compounds discussed in this article are the subject of ongoing research. Published data represents specific study populations and controlled conditions. Individual research applications should be designed with appropriate protocols and oversight.
Frequently Asked Questions
What is the difference between GHRH analogs and growth hormone secretagogues?
GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) activate the GHRH receptor on the pituitary, amplifying the size of natural GH pulses. Secretagogues (Ipamorelin, GHRP-2, GHRP-6, Hexarelin) activate the ghrelin receptor, initiating GH pulses. The two pathways are complementary and synergistic — combining one from each class produces greater GH responses than either alone.
Which growth hormone peptide has the fewest side effects in research?
Ipamorelin has the most selective profile — it stimulates GH release with minimal effects on cortisol, prolactin, or appetite. This selectivity makes it the “cleanest” secretagogue studied, which is why it’s commonly paired with CJC-1295 in research protocols.
Why is Tesamorelin the only FDA-approved GH peptide?
Tesamorelin was specifically developed and trialed for reduction of visceral fat in HIV-associated lipodystrophy — a condition with a clear unmet medical need. The pivotal trials published in NEJM showed significant and sustained visceral fat reduction, meeting the FDA’s efficacy threshold for that specific indication. Other GH peptides have been studied clinically but have not completed the Phase 3 trial and NDA process for specific indications.
Can GHRH analogs and secretagogues be combined in research?
Yes, combining a GHRH analog with a secretagogue is one of the most studied approaches in GH research. The CJC-1295 + Ipamorelin combination is the most common pairing — CJC-1295 amplifies GH pulse amplitude through the GHRH pathway while Ipamorelin triggers pulses through the ghrelin pathway. Published pharmacokinetic data shows the combination produces synergistic GH responses greater than either compound alone.
Products mentioned in this article: